Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02277314
Other study ID # 1404277367
Secondary ID
Status Recruiting
Phase N/A
First received October 24, 2014
Last updated January 11, 2016
Start date April 2014
Est. completion date April 2016

Study information

Verified date January 2016
Source University of Arizona
Contact Sue A Bulau, BA, AAS
Phone 520-694-1421
Email SueAnnBulau@uahealth.com
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The overall objective is to determine the visual outcomes and cost to perform Manual Small Incision Cataract Surgery (MSICS) in a small cohort at an academic medical center in the United States. The primary outcome measure will be the percentage of the study group achieving a post operative visual acuity 20/40 Snellen. This percentage will be compared to historical cohorts reported for phacoemulsification cataract surgery (PCS), when performed in academic centers. A secondary outcome will be to determine the actual institutional cost of providing MSICS in the setting of an academic medical center. The hypothesis is that MSICS is appropriate for a teaching environment (as evidenced by a comparable rate of 20/40 acuity or better at 90 days post op, as compared to PCS), and can be provided at a cost that makes visual rehabilitation affordable to the uninsured and underinsured.


Description:

The investigator will perform a study of a pilot implementation of portions of the Aravind method of promoting access to care and provision of surgical services in the setting of an academic medical center teaching program. Target enrollment is 100 subjects having cataracts. Potential subjects will be identified through vision screening programs and if cataracts are found they will be offered MSICS at a price deemed to be affordable by individuals without insurance.

A survey of Pima County providers found that $3500 was the lowest price offered to a self-pay patient for one-stage cataract extraction (CPT 66984) for PCS facility fee, surgeon fee, and anesthesia fee. The expectation is that MSICS can be delivered in a teaching environment at a cost of $500. The investigator wishes to determine if this price point is sustainable and if a continuing model of cataract visual rehabilitation service delivery can be safely, affordably, and ethically delivered to those who cannot afford to pay, while integrating resident education and autonomy into the delivery model.

The proposed outcome measure is the proportion of eyes that see 20/40 or better while wearing glasses for those participants that do not have comorbid conditions.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date April 2016
Est. primary completion date April 2016
Accepts healthy volunteers No
Gender Both
Age group 21 Years and older
Eligibility Inclusion Criteria:

1. Age 21 years or older (adults).

2. Medically Stable, able to safely undergo surgery.

3. Nuclear sclerotic cataract

4. Preoperative best corrected visual acuity (BCVA) 20/80 or worse

5. Expected post-operative potential acuity of 20/40 or better

6. Able to pay the $500 cost of surgery at the time of surgery

Exclusion Criteria:

Potential subjects not satisfying any of the above

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Manual Small Incision Cataract Surgery
This cost-effective solution for removing cataracts, also known as Manual Small Incision Cataract Surgery (MSICS), is a positive alternative when Phaco is not an option due to costs. The procedure takes approximately 30 minutes and involves a mid-size incision and an intraocular lens (IOL), or artificial lens, replacing the natural lens. Following the procedure, patients may need glasses, and most will need bifocals, but overall vision will be significantly improved.

Locations

Country Name City State
United States University of Arizona Medical Center Alvernon Physician Offices Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
University of Arizona

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Manual Small Incision Cataract Surgery with outcomes of 20/40 or better at the end of a year and with spectacle correction Post-cataract surgery the subject must have a visual acuity of 20/40 or better with spectacle correction 2 years No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06005675 - User Acceptability Evaluation of Pseudophakic Patients Previously Implanted With the TECNIS Odyssey IOL
Active, not recruiting NCT01382641 - Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery Phase 4
Completed NCT01382823 - Laser Cataract Surgery With the Femtosecond Laser Technology Phase 4
Completed NCT05991960 - Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL
Active, not recruiting NCT05574959 - Clinical Investigation of the TECNIS® Next-Generation Intraocular Lens, Model DEN00V N/A
Completed NCT02492659 - Clinical Research of Femtosecond Laser-Assisted Cataract Surgery N/A
Completed NCT01279031 - Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial Phase 4
Completed NCT00999492 - Selection of Aspheric Diffractive Multifocal Intraocular Lens (IOLS) Based on Corneal Wavefront Phase 4
Completed NCT01061463 - Occupational Cataracts and Lens Opacities in Interventional Cardiology : the O'CLOC Study N/A
Completed NCT01001806 - A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification Phase 4
Completed NCT01021761 - A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification Phase 4
Completed NCT00542581 - Acrysof Toric SN60T3corneal Astigmatism Between 0.75 and 1.00 D. N/A
Completed NCT03708367 - A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice N/A
Completed NCT05575063 - Clinical Investigation of Healon EndoCoat Ophthalmic Viscosurgical Device (OVD) N/A
Recruiting NCT05531292 - PROOF-OF-CONCEPT STUDY FOR NEW INTRAOCULAR LENS, MODEL C0002 N/A
Completed NCT05058274 - Clinical Results of a Monofocal Aspheric Bitoric Intraocular Lens With Plate Haptics in Hyperopic Eyes (HIPER-AT-TORBI)
Completed NCT05053399 - Evaluation of the TECNIS Symfony® Toric Intraocular Lens N/A
Recruiting NCT02639845 - Eye Drop Application Monitor, Pilot Study N/A
Completed NCT01684007 - A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients N/A
Completed NCT00827073 - Comparison of Tetracaine 0.5% and Lidocaine 2% Jelly for Topical Phacoemulsification Cataract Surgery N/A